Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC

NCT04455594 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

168

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer Stage IIIA

Interventions

DRUG: Almonertinib
DRUG: Erlotinib
DRUG: Cisplatin
DRUG: Carboplatin
DRUG: Pemetrexed

Sponsor

The First Affiliated Hospital of Guangzhou Medical University